In a report released today, Madhu Kumar from B.Riley FBR reiterated a Hold rating on Assembly Biosciences (NASDAQ: ASMB), with a price target of $42. The company’s shares closed yesterday at $47.73.
Kumar noted:
“Biosciences (ASMB) hosted its first a focus on chronic hepatitis B virus (HBV) infection. While we are positive on the greater visibility on upcoming Phase IIa studies of lead asset, HBV core inhibitor ABI-H0731, we await top-line clinical data from the Phase IIa trials, guided for 1H19, to substantially improve our outlook on ASMB shares. We thus reiterate our ASMB Neutral rating and $42 price target.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 39.0% and a 59.3% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Clementia Pharmaceuticals Inc, Deciphera Pharmaceuticals Inc, and Iovance Biotherapeutics Inc.
Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $62.75.
See today’s analyst top recommended stocks >>
Based on Assembly Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.25 million. In comparison, last year the company had a GAAP net loss of $13.93 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
